Compare Moderna, Inc. (MRNA) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PAGSEG Inc — how do they compare? Moderna, Inc. trades at $136.47 (market cap $56.02B), while PAGSEG Inc trades at $9.6 (market cap $2.69B). The key difference: Moderna, Inc. is far larger — about 20.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.49% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PAGS | |
|---|---|---|
Market Cap | $56.02B | $2.69B |
Sector | Health | Technology |
52-Week High | $174.38 | $12.00 |
52-Week Low | $22.36 | $8.44 |
Enterprise Value | $52.17B | $10.60B |
Dividend Yield | — | 11.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
PAGS trades at $9.75, up 0.21% today, with a bullish technical signal from moving averages and a consensus analyst price target of $11.45. The company reported Q2 2026 EPS of $0.41, beating expectations, and maintains solid fundamentals with a P/E of 6.67 and net income margin of 10.45%. Recent news highlights institutional investments and management continuity despite leadership changes.
The outlook is positive with attractive valuation and growth potential, but risks include macroeconomic challenges in Brazil and competitive pressures. Upside is supported by analyst buy ratings and dividend payments, though investors should monitor credit loss trends and interest rate impacts on profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
